Intrinsic Therapeutics Inc. says a 554-patient randomized, superiority trial supports use of its Barricaid device following a standard spine procedure to prevent re-herniation and recurrence of pain or dysfunction. In December, a US FDA advisory panel will weigh the evidence.
The agency issued a notice Oct. 16 announcing that its Orthopaedic and Rehabilitation Devices Panel will meet Dec. 12 to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?